CompoAtlas

SX-7 #Shatter

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
3-Aminopropanoic acid1.200 mgNicht berechnet
1,3,7-Triméthylxanthine150 mgNicht berechnet
Adénosine 5'-(disodium triphosphate)

Quelle : Adénosine triphosphate disodium

200 mgNicht berechnet
Myristica fragrans

Quelle : Graine(s)

Extraktionsverhältnis : 5:1

Trockenpflanzenäquivalent : 500 mg

100 mgNicht berechnet
Ocimum tenuiflorum

Quelle : Feuille

Extraktionsverhältnis : 5:1

Trockenpflanzenäquivalent : 250 mg

50 mgNicht berechnet
Citrus aurantium

Quelle : Fruit

Extraktionsverhältnis : 15:1

Trockenpflanzenäquivalent : 375 mg

25 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Saveur de citron-lime, Blue raspberry flavor, Saveur de fraise, Acid citrique, Sucralose, Saveur de punch aux fruits, Watermelon flavour, Acesulfame Potassium, Poly(dextrose), rouge de betterave, Acide DL-malique

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultesminimum : 18 ansminimum : 1 Mesures ; maximum : 2 Mesures1 Tous les jours

In Kanada zugelassene Verwendungen

Helps (temporarily) to promote alertness and wakefulness, and to enhance cognitive performance. Helps (temporarily) to relieve fatigue, to promote endurance, and to enhance motor performance. Helps increase lean mass when used in conjunction with a resistant training regimen and a healthy balanced diet. Helps improve strength and performance in repetitive bouts of brief, highly intense physical activity in conjunction with a healthy balanced diet.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Known Adverse Reactions : Hypersensitivity/allergy has been known to occur, in which case, discontinue use.

Originaltext auf Englisch.

Contra-Indications : Consumption with other caffeine-containing products (e.g. medications, coffee, tea, colas, cocoa, guarana, maté) is not recommended. Consumption with natural health products (e.g. bitter orange extract, synephrine, octopamine, ephedra) or other drugs (e.g. ephedrine) which increase blood pressure is not recommended. Consult a health care practitioner prior to use if you are taking lithium.

Originaltext auf Englisch.

Cautions and Warnings : Not intended for use for persons under 18. Do not use if you are pregnant, nursing or attempting to conceive. Do not use if you have cardiovascular disease risk factors (e.g. high blood pressure, high cholesterols and/or triglycerides, obesity) or glaucoma. Consult a health care practitioner before starting any diet or exercise program. Do not exceed recommended serving. Improper use of this product will not improve results and it is not advised. Use only as directed. Keep out of reach of children. Discontinue use and consult a health care practitioner if you experience unusual symptoms. Consult a health care practitioner prior to use if you have been treated for, diagnosed with or have family history of any medical condition, or if you are using any prescription or over-the-counter drug(s), including blood thinners. If you are taking any heart or blood pressure medication, consult a health care practitioner prior to use. One serving of this product contains as much caffeine as approximately 1.5 cups of coffee. Caffeine sensitive individuals may experience the following symptoms including (but not limited to), restlessness, nervousness, tremors, headache, anxiety, palpitations, increased heart rate, or difficulty sleeping; in which case discontinue use and consult a health care practitioner. This product is not intended as a substitute for sleep. Maintain an adequate state of hydration before, during, and after exercise. If you are taking anti-depressants, such as monoamine oxidase inhibition (MAOIs) consult a health care practitioner prior to use. If you suffer from heartburn or acid reflux, consult a health care practitioner prior to use. May cause a flushing, tingling and/or prickling sensation of the skin, in which case, reduce the dose. Caffeine has been shown to reduce blood flow to the heart muscle during exercise which might lead to cardiovascular complications such as chest pain, spasm and irregular heartbeat even in healthy individuals. If those symptoms occur discontinue use and consult a health care practitioner. Consult a health care practitioner prior to use if you have detrusor instability (overactive bladder syndrome). Consult a health care practitioner prior to use if you have cardiovascular disease or hypertension, diabetes, prostate disorders or are taking prescription medication. Do not consume if you are taking decongestant-containing cold preparations, i.e. phenylephrine or pseudoephedrine, products containing ephedra or ephedrine, or other medications that increase blood pressure.

Originaltext auf Englisch.

Produktdaten

Inhaber
Iovate Health Sciences International Inc.
NPN oder DIN-HM
80054742
Status
Aktive Lizenz
Lizenzdatum
10. Oktober 2014
Überarbeitungsdatum
Nicht angegeben
Form
Poudre
Verabreichungsweg
Orale
Art des Antrags
Non traditionnelle

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80054742

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • Ocimum tenuiflorum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    HOLY BASIL - OCIMUM TENUIFLORUM - SEED

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular condition (Rai et al. 1997; Agrawal et al. 1996).

    Von Health Canada zitierte Quellen (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).

    Von Health Canada zitierte Quellen (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed

    Anwendungsbedingung: Relief of cough; Digestive aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 27. Februar 2026

    HOLY BASIL - OCIMUM TENUIFLORUM - LEAF

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (WHO 2002).

    Von Health Canada zitierte Quellen (2)
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a heart condition or diabetes (Rai et al. 1997; Agrawal et al. 1996).

    Von Health Canada zitierte Quellen (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).

    Von Health Canada zitierte Quellen (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomisierte Studie
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed

    Anwendungsbedingung: Relief of cough/cold/respiratory mucus buildup; Digestive aid; Adaptogen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Gegenanzeigen

    Do not use if you are pregnant (Prakash et al. 2005; Ahmed et al. 2002; WHO 2002; Wohlmuth 2002; Kapoor 2001).

    Von Health Canada zitierte Quellen (6)
    • Ahmed A, Ahamed RN, Aladakatti RH, Ghoseawar MG. Reversible antifertility effect of benzene extract of Ocimum sanctum on sperm parameters and fructose content in rats. Journal of basic and clinical physiology and pharmacology 2002;13:51-59. PubMed
    • Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Baton Roca (FL): CRC Press LLC; 2001.
    • Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: A short review. Indian Journal of Physiology and Pharmacology 2005;49(2):125-131. PubMed Übersichtsartikel
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
    • Wohlmuth H. Sacred basil - an Ayurvedic adaptogen. Botanical Pathways, 2002; Issue 11.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.

    Monografie von Health Canada vom 27. Februar 2026

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Das Belegdatum dieser Zutatenliste ist unbekannt.

Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile